They joined us !
Creation : November 2024
Employees : 5
Adress : Grenoble
Activity (biotech/medtech/healthtech) : biotech
Who ?
Peripheral neuropathies affect millions of people and share multiple origins. The available treatment options are palliative and ineffective. Saxol is redefining the management with Carba compounds. Thanks to a novel mechanism of action, 1st in-class, Carba is positioned as an innovative game changer, allowing a breakthrough transition from palliative to preventive in order to properly address significant unmet medical needs. First, we plan to demonstrate efficacy in the indication of chemotherapy-induced peripheral neuropathies before expanding its use.
Why joined us ?
“A very strong desire to join a group of innovative actors working in the health sector in order to share good practices, experiences and help each other.”
Philippe BORDEAU
CEO